Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00469781|
Recruitment Status : Completed
First Posted : May 7, 2007
Last Update Posted : September 25, 2008
|Condition or disease||Intervention/treatment||Phase|
|Cystoid Macular Edema, Retinal Thickening||Drug: 2. Xibrom (Bromfenac) Drug: 1. Pred Forte||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||95 participants|
|Intervention Model:||Parallel Assignment|
|Study Start Date :||May 2007|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
|Active Comparator: 1||
Drug: 1. Pred Forte
Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.
Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks.
Drug: 2. Xibrom (Bromfenac)
Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
- Cystoid Macular Edema [ Time Frame: 11 months ]
- Retinal Thickening [ Time Frame: 11 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00469781
|United States, Florida|
|The Center for Excellence in Eye Care|
|Miami, Florida, United States, 33176|
|Principal Investigator:||Carlos Buznego, MD||The Center for Excellence in Eye Care|